Try it
Pharmacology · Endocrine drugs: phosphate binder choice in dialysis
Sample itemA haemodialysis patient taking calcium carbonate has a serum calcium of 11.0 mg/dL and a phosphate of 7.5 mg/dL. Which change is most appropriate?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
B. Switch to sevelamer
Sevelamer is a non-absorbed, calcium-free polymer that binds dietary phosphate in the gut and also lowers LDL cholesterol. It lowers phosphate without adding to calcium load. Lanthanum is another non-calcium binder. Aluminium hydroxide causes aluminium toxicity with long use.
Option by option
A. Add long-term aluminium hydroxide
Long-term aluminium causes encephalopathy, bone disease and anaemia.
B. Switch to sevelamer (correct)
Correct. A non-calcium binder lowers phosphate without further raising calcium.
C. Add calcitriol
Calcitriol increases gut absorption of both calcium and phosphate, and would worsen both.
D. Increase the calcium carbonate dose
More calcium carbonate would worsen the hypercalcaemia.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Pharmacology questions
- Emergency drugsA patient develops stridor, wheeze and hypotension minutes after an injection. What is t…
- AntiepilepticsWhat is the preferred first-line drug for a patient in generalised convulsive status epi…
- AntimicrobialsWhich drug can cause a disulfiram-like reaction when taken with alcohol?
- AntiepilepticsWhich drug is preferred for uncomplicated childhood absence seizures?